Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Boosted by Franklin Resources Inc.

Franklin Resources Inc. raised its position in Hologic, Inc. (NASDAQ:HOLX) by 171.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 278,295 shares of the medical equipment provider’s stock after purchasing an additional 175,855 shares during the quarter. Franklin Resources Inc. owned about 0.12% of Hologic worth $22,714,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Innealta Capital LLC acquired a new position in Hologic during the 2nd quarter valued at about $25,000. Wolff Wiese Magana LLC bought a new stake in Hologic during the third quarter worth approximately $25,000. Groupama Asset Managment lifted its position in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Sunbelt Securities Inc. bought a new position in Hologic during the 2nd quarter valued at $37,000. Finally, First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HOLX shares. JPMorgan Chase & Co. lifted their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada increased their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Raymond James boosted their price objective on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Finally, Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $89.50.

Hologic Stock Down 1.0 %

Shares of NASDAQ HOLX opened at $70.76 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a market cap of $16.06 billion, a PE ratio of 21.25, a P/E/G ratio of 2.38 and a beta of 0.96. The company’s fifty day simple moving average is $78.65 and its 200 day simple moving average is $78.52. Hologic, Inc. has a 12-month low of $70.24 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the business earned $0.89 EPS. Hologic’s quarterly revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.